Fluticasone propionate and salmeterol 100/50 powder ^en

mid: /m/0hqv034 notable type: /medicine/drug_formulation

Fluticasone propionate and salmeterol powder, for respiratory (inhalation) / oral administration, consisting of: 100ug fluticasone propionate ; 50ug salmeterol xinafoate.Indications:ADVAIR DISKUS is a combination product containing a corticosteroid and a LABA indicated for: Treatment of asthma in patients aged 4 years and older. (1.1)Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). (1.2) Important limitation: Not indicated for the relief of acute bronchospasm. (1.1, 1.2) [ - ]

Types:

Add type

Metaweb System Types

Object

Common

Topic

Medicine

Drug formulation

Freebase

Object profile

Object is not asserted on this topic.

ID /type/object/id

GUID /type/object/guid

#9202a8c04000641f800000001f6d0064

Type /type/object/type

Drug formulation
Topic

Name /type/object/name

- - Edit
  - Delete
Fluticasone propionate and salmeterol 100/50 powder

Key /type/object/key

- - Edit
  - Delete
/base/medicaldrugs/fda_load/form_O2GMZ0LF5W_100_0ug_6EW8Q962A5_50_0ug_powder_oral_respiratory__inhalation_

Timestamp /type/object/timestamp

Saturday, January 07, 2012 8:45 AM

Permission /type/object/permission

/boot/all_permission

Creator /type/object/creator

fda_medical_bot

Attribution /type/object/attribution

fda_medical_bot

Search /type/object/search

Machine ID /type/object/mid

/m/0hqv034

Also known as /common/topic/alias

Description /common/topic/description

- - Edit
  - Delete
Fluticasone propionate and salmeterol powder, for respiratory (inhalation) / oral administration, consisting of: 100ug fluticasone propionate ; 50ug salmeterol xinafoate.Indications:ADVAIR DISKUS is a combination product containing a corticosteroid and a LABA indicated for: Treatment of asthma in patients aged 4 years and older. (1.1)Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). (1.2) Important limitation: Not indicated for the relief of acute bronchospasm. (1.1, 1.2)